|

A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC

RECRUITINGPhase 2Sponsored by The First Affiliated Hospital of Guangzhou Medical University
Actively Recruiting
PhasePhase 2
SponsorThe First Affiliated Hospital of Guangzhou Medical University
Started2024-09-24
Est. completion2025-12-31
Eligibility
Age18 Years – 65 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06775275

Summary

This is a prospective, multicenter, randomized, uncontrolled Phase II study to assess the efficacy and safety of adebrelimab in combination with chemotherapy with or without bevacizumab for the treatment of resectable Stage II-IIIB (T3N2) NSQ-NSCLC and to explore biomarkers associated with efficacy.

Eligibility

Age: 18 Years – 65 YearsHealthy volunteers accepted
Inclusion Criteria:

* Resectable NSQ NSCLC
* Age 18-65 years
* male or female
* ECOG 0-1
* Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
* Subjects must have adequate pulmonary function for the intended pneumonectomy;

Exclusion Criteria:

* SCLC or SQ NSCLC
* previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
* patients who have previously used anti-angiogenic drugs;
* allergic to any component of the study drug or chemotherapy drugs
* patients with any severe and or uncontrolled disease

Conditions3

CancerLung CancerResectable Lung Non-Small Cell Carcinoma

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.